Skip to main content

Year: 2023

Intra-Oral Flat Panel Sensor Market Size to Reach USD 500 Million in 2032 | Emergen Research

Rising demand for intra-oral flat panel sensors in dental imaging is a key factor driving Intra-Oral Flat Panel Sensor market revenue growth Vancouver, Dec. 26, 2023 (GLOBE NEWSWIRE) — The global intra-oral flat panel sensor market size was USD 337 Million in 2022 and is expected to register a steady revenue CAGR of 4% during the forecast period, according to latest analysis by Emergen Research. Rising demand for intra-oral flat panel sensors in dental imaging is a key factor driving market revenue growth. Intra-oral flat panel sensors are critical diagnostic components that are designed to be placed within the patient’s oral cavity. These sensors can collect very detailed images that provide the dentist with crucial diagnostic information. In addition, increasing use of dental imaging technology due to rising prevalence...

Continue reading

Inductive Encoder Market Growth CAGR 8.3% During 2022-2032 | Emergen Research

Rising demand for inductive encoders in industrial automation is a major factor driving the Inductive Encoder market revenue growth. Vancouver, Dec. 26, 2023 (GLOBE NEWSWIRE) — The global inductive encoder market size was USD billion in 2022 and is expected to register a revenue CAGR of 8.3% during the forecast period, according to the latest analysis by Emergen Research. Increasing adoption of inductive encoders in industrial automation equipment such as robotic arms, actuators, conveyors, and other moving components are driving market revenue growth.Inductive encoder is designed to detect accurate, precise, and calibrated positions. Globally, an array of industries is adopting the industry ‘4.0’ paradigm, which frames development of various digital technologies as the fourth industrial revolution. Modern industrial...

Continue reading

Global Power Steering Pump Market Size Worth USD 5.02 Billion in 2032 | Emergen Research

Increasing focus on considering enhanced Noise, Vibration, and Harshness (NVH) control and integration of sensor technologies is a major factor driving the Power Steering Pump market revenue growth. Vancouver, Dec. 26, 2023 (GLOBE NEWSWIRE) —  The global power steering pump market size was USD 1.74 Billion in 2022 and is expected to register a revenue CAGR of 3.1% during the forecast period, according to latest analysis by Emergen Research. Increasing focus on considering enhanced Noise, Vibration, and Harshness (NVH) control in power steering pump design is a major factor driving the market revenue growth. Manufacturers are employing advanced techniques, such as improved pump rotor profiles, vibration-dampening technologies, and noise reduction measures, to minimize noise and vibration levels. This ensures a smoother and quieter...

Continue reading

SEALSQ Appoints Vice President of Global Sales

Tortola, British Virgin Islands, Dec. 26, 2023 (GLOBE NEWSWIRE) — SEALSQ Appoints Vice President of Global Sales December 26, 2023: SEALSQ Corp (“SEALSQ” or “Company”) (NASDAQ: LAES), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced the appointment of Franck Buonanno as Vice President of Global Sales for its Semiconductor and PKI activities, effective immediately. Mr. Buonanno joined WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN; Nasdaq: WKEY), SEALSQ’s parent company, in August 2021 as Director of Sales for Europe. In his new role as Vice President of Global Sales for SEALSQ, Mr. Buonanno will be responsible for leading the Company’s global sales efforts. With a career spanning three decades...

Continue reading

iBio Amends and Extends Maturity of Credit Agreement

– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business – BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into an amendment (the “Amendment”) to the Credit Agreement dated November 1, 2021 (the “Agreement”), extending the Agreement’s maturity date from December 31, 2023 to the earlier March 29, 2024, or the acceleration of maturity of the term loan in accordance with the Credit Agreement. “We are pleased to have worked constructively with Woodforest to execute this amendment and extension of the maturity...

Continue reading

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) — Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion...

Continue reading

Teleflex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WAYNE, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) — Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 42nd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on Tuesday, January 9, 2024, at 3:00 p.m. (PT). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access,...

Continue reading

Fusion Acquisition Corp. II Announces Redemption of Shares

NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) — Fusion Acquisition Corp. II today announced that its board of directors (the “Board”) has determined to redeem all of its outstanding shares of Class A common stock (the “Public Shares”), effective as of December 28, 2023, because the Company will not consummate an initial business combination within the time period required by its amended and restated certificate of incorporation. As of the close of business on December 28, 2023, the Public Shares will be deemed cancelled and will represent only the rights to receive the per-share redemption price of approximately $10.67 (after taking into account the removal of a portion of the accrued interest in the trust account to pay taxes and $100,000 for dissolution expenses). In order to provide for the disbursement of funds from the trust account,...

Continue reading

AirNet Technology Inc. Announces Unaudited Financial Results for the First Half of 2023

BEIJING, Dec. 26, 2023 (GLOBE NEWSWIRE) — AirNet Technology Inc., formerly known as AirMedia Group Inc. (“AirNet” or the “Company”) (Nasdaq: ANTE), today announced its unaudited financial results for the first half of 2023.AIRNET TECHNOLOGY INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. dollars in thousands, except share and per share data)    As of December 31,   As of June 30,      2022   2023          (Unaudited)  Assets              Current assets:              Cash and cash equivalents   $ 2,700   $ 132  Accounts receivable, net     1,421     552  Other current assets, net     65,072     28,527  Amount due from related parties     601     199  Total current assets     69,794     29,410  Property and equipment, net     10,885     10,447  Long-term investments, net     34,083     30,654  Long-term...

Continue reading

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize potential first-in-class radioenhancer NBTXR3 in China, South Korea, Singapore, and Thailand. “Our collaboration strategy for the development and commercialization of NBTXR3 is rooted in a shared commitment to delivering the potential first-in-class radioenhancer to millions of patients around the world,” said Laurent Levy, Nanobiotix...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.